Alendronic acid
- Generic Name
- Alendronic acid
- Brand Names
- Adrovance, Binosto, Fosamax, Fosamax Plus D, Fosavance
- Drug Type
- Small Molecule
- Chemical Formula
- C4H13NO7P2
- CAS Number
- 66376-36-1
- Unique Ingredient Identifier
- X1J18R4W8P
- Background
Alendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease. It functions by preventing resorption of bone.
- Indication
Alendronic acid is indicated for the treatment and prevention of osteoporosis in men and postmenopausal women, treatment of glucocorticoid-induced osteoporosis, and Paget's disease of bone. However, alendronic acid is not indicated for use in pediatric populations or patients with a creatinine clearance <35mL/min.
- Associated Conditions
- Osteogenesis Imperfecta (OI), Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Paget’s Disease
- Associated Therapies
- -
When It Comes to Space Precision Medicine, the Sky Is the Limit—Literally
Spaceflight alters drug integrity and human body responses, necessitating pharmacogenomics for long-term habitation on the Moon. Research identifies key genes impacting drug processing and immune function, with microgravity affecting cell behavior and health. Collaboration aims to enhance pharmaceutical data access and predict drug responses in space.
Sex differences of fall-risk-increasing drugs in the middle-aged and elderly
101,746 AE reports analyzed, 68,492 (67.3%) female, 32,547 (32.0%) male; average age 69.8 ± 11.5 (female), 71.5 ± 11.2 (male). Report numbers fluctuated since 2004, peaking 2010-2012 and 2018-2019. Most reports from America (62.3% female, 55.4% male), mainly hospitalization (51.3% female, 51.2% male). Multiple sclerosis most reported AE (14.2% female, 6.2% male). Signals detected using ROR and BCPNN algorithms; top signals varied by sex. Sex differences in signal numbers noted in 2nd-level ATC classes. F/M ratio analysis on shared signals showed 33 positive for females, 38 for males, 48 no difference. Specific drugs showed stronger associations with falls in one sex over the other across various ATC classifications.
Has Albrecht Been Undone? | Insights
Eric Alexander discusses the Supreme Court's decision in Merck Sharp & Dohme Corp. v. Albrecht and its impact on preemption defense in failure-to-warn claims for branded prescription drugs, focusing on the Fosamax MDL and the Third Circuit's Fosamax II decision.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath